2-n-propylquinoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-propylquinoline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	74166
CHEMBL ID	354607
SCHEMBL ID	725176
MeSH ID	M0298468

Synonyms (11)

Synonym
2-propylquinoline
quinoline, 2-propyl-
AKOS006370675
2-n-propylquinoleine
2-propyl-quinoline
CHEMBL354607
1613-32-7
SCHEMBL725176
IZXJPGLOYYDHRM-UHFFFAOYSA-N
DTXSID80167105
2-n-propylquinoline

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" The pharmacokinetics of 2-n-PQ in rats showed that after an intravenous treatment of the formulation at 10mgkg(-1), the plasma drug concentrations rapidly declined bi-exponentially with a half-life of 58."	( In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β-cyclodextrin formulation and pharmacokinetics via intravenous route. Balaraman, K; Bories, C; Cojean, S; Figadère, B; Kesavan, V; Loiseau, PM; Moussa, F; Pomel, S; Vacus, J; Vieira, NC, 2015)	0.67

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay ID	Title	Year	Journal	Article
AID776404	Drug metabolism in mouse liver microsomes at 1 uM after 30 mins by LC-MS/MS analysis	2013	European journal of medicinal chemistry, Nov, Volume: 69	Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID84649	Inhibitory activity against human T-lymphotropic virus type 1 (HTLV-1) infected HUT-102 cells at 10 uM	2003	Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5	Substituted quinolines induce inhibition of proliferation of HTLV-1 infected cells.
AID776405	Solubility of the compound	2013	European journal of medicinal chemistry, Nov, Volume: 69	Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID776406	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Leishmania donovani MHOM/IN/80/Dd8 amastigotes	2013	European journal of medicinal chemistry, Nov, Volume: 69	Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID776408	Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 amastigotes infected in mouse J774A1 cells assessed as parasite growth inhibition after 72 hrs by luciferase reporter gene assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID776403	Drug metabolism in human liver microsomes at 1 uM after 30 mins by LC-MS/MS analysis	2013	European journal of medicinal chemistry, Nov, Volume: 69	Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID776407	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
AID1845743	Antileishmanial activity against promastigote form of Leishmania braziliensis assessed as parasite growth inhibition	2021	Bioorganic & medicinal chemistry, 02-15, Volume: 32	A comprehensive review on the biological interest of quinoline and its derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (11.11)	18.2507
2000's	4 (44.44)	29.6817
2010's	3 (33.33)	24.3611
2020's	1 (11.11)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.55 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	4.95 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.55)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (10.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (90.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	2.06	1	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	2.48	2	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	2	1	C-nitro compound; imidazoles	antitubercular agent
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	3.41	1	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2	1	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
acarbose [no description available]	3.41	1	tetrasaccharide derivative	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; geroprotector; hypoglycemic agent
2-phenylquinoline 2-phenylquinoline: structure in first source	2.01	1
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.11	1	cyclodextrin
nadp [no description available]	2.01	1
styrylquinoline styrylquinoline: structure in first source	2.01	1	2-styrylquinoline

Condition	Relationship Strength	Studies
Human T-lymphotropic Virus 1 Infection [description not available]	2.01	1
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	2.01	1
HTLV-I Infections Diseases caused by HUMAN T-LYMPHOTROPIC VIRUS 1.	2.01	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.97	4
Black Fever [description not available]	2.78	3
Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.	2.78	3
Chronic Illness [description not available]	2	1
American Trypanosomiasis [description not available]	2	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2	1
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	2	1

chemdatabank.com